Future growth expectations in sales/revenue/volumes?

The company targets a revenue growth CAGR of 18% to 20% over the next 3 to 5 years. They expect exports to increase to about 60% of total sales, with domestic sales around 40%. Capacity expansion of around INR 250-270 crores over 2-3 years aims to add approximately INR 1,000 crores in revenue. Current capacity utilization is about 90% for technicals and 55% for formulations, expected to rise with new registrations. New product launches include 4-5 products planned for FY23 and similar numbers for FY24, focusing on herbicides, fungicides, and insecticides. The product pipeline aims for $600-$70

Any current/future new fundraising through debt or equity?

There is no specific mention of any planned fundraising through debt or equity in the current or future period. The company plans to fund its CAPEX of around ₹250 crore over the next two to three years mostly through internal accruals. They have good internal accruals currently and expect to use surplus cash generated for investments, registrations, new geographies, and new products. Management is open to inorganic acquisitions if good synergistic opportunities arise, supported by strong capital accruals. No explicit intention to raise external debt or equity was indicated during the discussio

Any current/future capex/capital investment/strategic investment?

Heranba Industries plans CAPEX of around ₹250-270 crores over the next 2-3 years, mainly funded through internal accruals. Approximately 70% of this CAPEX is directed toward capacity expansion for new products, with the remaining 30% for existing products. New technical capacity addition expected in phases, potentially adding 5,000 to 10,000 metric tons. A new technical manufacturing site is planned to start operations by Q3 (September-October). The company aims to leverage surplus cash generated (estimated ₹600-650 crores operating cash flow over FY22-FY24) for new investments including regis

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth at a CAGR of 18% to 20% over the next 3 to 5 years. EBITDA margins are expected to be maintained around 18% to 19%, with potential for improvement due to new product launches. Gross margins are anticipated to be stable around 35% to 36% on a full-year basis. Earnings per share (EPS) showed a strong 61.75% increase y-o-y recently, indicating robust profit growth. Operating profits increased significantly in FY21 and are expected to sustain with new registrations and geographical expansion. New product launches, especially in technicals and formulations, as wel

Heranba IndsQ1 FY22Fertilizers & Agrochemicals

Heranba Inds Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹159.91Market Cap: ₹640 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company targets a revenue growth CAGR of 18% to 20% over the next 3 to 5 years.
They expect exports to increase to about 60% of total sales, with domestic sales around 40%.
Capacity expansion of around INR 250-270 crores over 2-3 years aims to add approximately INR 1,000 crores in revenue.
Current capacity utilization is about 90% for technicals and 55% for formulations, expected to rise with new registrations.
New product launches include 4-5 products planned for FY23 and similar numbers for FY24, focusing on herbicides, fungicides, and insecticides.
The product pipeline aims for $600-$700 million opportunity size in US, Europe, and LATAM markets.
Management targets sustaining or improving EBITDA margins around 18-19%.
Growth driven by both volume and value increases, supported by internal accruals and potential inorganic opportunities.

Margin guidance

Category 3

The company expects revenue growth at a CAGR of 18% to 20% over the next 3 to 5 years.
EBITDA margins are expected to be maintained around 18% to 19%, with potential for improvement due to new product launches.
Gross margins are anticipated to be stable around 35% to 36% on a full-year basis.
Earnings per share (EPS) showed a strong 61.75% increase y-o-y recently, indicating robust profit growth.
Operating profits increased significantly in FY21 and are expected to sustain with new registrations and geographical expansion.
New product launches, especially in technicals and formulations, as well as expansion in exports to US, Europe, and LATAM, will drive growth.
Capital expenditure of about ₹250-270 crores over 2-3 years aims at capacity expansion and new product development, funded mainly through internal accruals.
Management remains open to inorganic growth opportunities to utilize surplus cash post-capex.

See what Heranba Inds management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any planned fundraising through debt or equity in the current or future period.
The company plans to fund its CAPEX of around ₹250 crore over the next two to three years mostly through internal accruals.
They have good internal accruals currently and expect to use surplus cash generated for investments, registrations, new geographies, and new products.
Management is open to inorganic acquisitions if good synergistic opportunities arise, supported by strong capital accruals.
No explicit intention to raise external debt or equity was indicated during the discussion.

Order book

- The transcript does not provide explicit details on the current or expected order book or specific pending orders in terms of volume or value. - It is mentioned that demand is strong, but exports are slightly delayed due to logistical challenges like container scarcity, causing slower movement rather than lost demand. - The company has orders in place for both domestic and export markets, with domestic growth noted as strong (90% growth) and export orders pending but with slow dispatch due to logistics. - The company has ongoing registrations and product launches planned, indicating a healthy future demand pipeline. - New product launches and capacity expansions suggest expectations for increasing order inflow in the coming years. Therefore, while no precise order book figures are provided, the company indicates a robust demand environment with some export shipment delays affecting order fulfillment timing.

See what Heranba Inds management said on order book — free account, 30 seconds.

Capex plans

Yes

Heranba Industries plans CAPEX of around ₹250-270 crores over the next 2-3 years, mainly funded through internal accruals.
Approximately 70% of this CAPEX is directed toward capacity expansion for new products, with the remaining 30% for existing products.
New technical capacity addition expected in phases, potentially adding 5,000 to 10,000 metric tons.
A new technical manufacturing site is planned to start operations by Q3 (September-October).
The company aims to leverage surplus cash generated (estimated ₹600-650 crores operating cash flow over FY22-FY24) for new investments including registrations, new geographies, and product launches.
Management is open to inorganic growth and acquisitions if synergistic opportunities arise.
R&D plans include 4-5 new products launches each in FY23 and FY24, with additional pipeline development ongoing.

Track Heranba Inds — get its next earnings analysis in your feed

How does Heranba Inds rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisHeranba Inds

Rev 3Mar 3

See where Heranba Inds sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Heranba Inds rank in Fertilizers & Agrochemicals?

Compare Heranba Inds against every Fertilizers & Agrochemicals company (Q1 FY22) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Heranba Inds's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Bhagiradha Chemicals & Industries Ltd (Q2 FY26)
140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran
Krishana Phosch. (Q2 FY26)
Trading contributes around 20%–22% of total turnover; trading volumes may vary depending on market conditions. Key concall takeaways from Krishana Phoschem…
Bhagiradha Chemicals & Industries Ltd (Q3 FY26)
114.0 crore, up 11% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q3 FY26 investor presentation — and how it ran
Advance Agrolife Ltd (Q3 FY26)
Q3 FY26 revenue from operations was ₹1,338 million, up 18% year-on-year (YoY) from ₹1,134 million in Q3 FY25 (Pages 23-24). Key investor presentation takeaways

Compare:vs Coromandel Inter vs F A C T vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Heranba Inds Q1 FY22 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Heranba Inds rank in Fertilizers & Agrochemicals?

Continue your research

What Heranba Inds's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season